Male Contraceptive Options Near Approval

Ffion Storer Jones of Deutsche Stiftung Weltbevölkerung notes that modern contraception has largely been a woman’s responsibility for over sixty years. Despite decades of research, reversible male contraceptives remain unavailable, though several candidates are nearing potential approval.

YCT-529 is a non-hormonal daily pill in mid-stage trials, while Contraline develops ADAM, a hydrogel implant, and NES/T, a hormonal shoulder gel. Germany recently invested €11.6 million in four sex-inclusive contraception projects to run to 2029.

Final trials pose challenges due to the need for large, long-term safety studies, increasing costs and timelines. Regulators apply stricter risk-benefit calculations to male contraceptives, as men do not experience pregnancy. Early hormonal methods faced setbacks due to mild side effects.

More than 30 studies show growing male interest in new options, and many women would trust their partners to use them. Experts believe conversations are shifting, and investment is slowly increasing, suggesting a potential “second revolution” in contraception.